Evidence map›Paper›PMID 37975950›Full record

ArticlePurinergic signalling2024

Synthesis of new non-natural L-glycosidic flavonoid derivatives and their evaluation as inhibitors of Trypanosoma cruzi ecto-nucleoside triphosphate diphosphohydrolase 1 (TcNTPDase1).

Isadora Cunha Ribeiro, João Victor Badaró de Moraes, Christiane Mariotini-Moura, Marcelo Depolo Polêto, Nancy da Rocha Torres Pavione, Raissa Barbosa de Castro, Izabel Luzia Miranda, Suélen Karine Sartori, Kryssia Lohayne Santos Alves, Gustavo Costa Bressan and 4 more

Open access · greenAbstract read
In one paragraph

Article in Purinergic signalling, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Isadora Cunha RibeiroBiochemistry and Molecular Biology Department, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0003-1695-8080
João Victor Badaró de MoraesGeneral Biology Department, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-2654-3252
Christiane Mariotini-MouraGeneral Biology Department, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0003-1101-6895
Marcelo Depolo PolêtoBiochemistry and Molecular Biology Department, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0001-9210-690X
Nancy da Rocha Torres PavioneGeneral Biology Department, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-3126-3343
Raissa Barbosa de CastroBiochemistry and Molecular Biology Department, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-9285-6740
Izabel Luzia MirandaExact Science Institute, Chemistry Department, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0001-5528-669X
Suélen Karine SartoriExact Science Institute, Chemistry Department, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-7540-6764
Kryssia Lohayne Santos AlvesExact Science Institute, Chemistry Department, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-9817-5487
Gustavo Costa BressanBiochemistry and Molecular Biology Department, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-9741-4554
Raphael de Souza VasconcellosBiochemistry and Molecular Biology Department, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-5064-052X
José Roberto Meyer-FernandesLaboratory of Cellular Biochemistry, Institute of Medical Biochemistry Leopoldo de Meis, Health Sciences Center, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.ORCID https://orcid.org/0000-0003-2728-3138
Gaspar Diaz-MuñozExact Science Institute, Chemistry Department, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. gaspardm@qui.ufmg.br.ORCID https://orcid.org/0000-0002-7515-0420
Juliana Lopes Rangel FiettoBiochemistry and Molecular Biology Department, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil. jufietto@ufv.br.ORCID https://orcid.org/0000-0001-6122-1710
Universidade Federal de Viçosa · BRUniversidade Federal de Minas Gerais · BRUniversidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trypanosoma cruzi is the pathogen of Chagas disease, a neglected tropical disease that affects more than 6 million people worldwide. There are no vaccines to prevent infection, and the therapeutic arsenal is very minimal and toxic. The unique E-NTPDase of T. cruzi (TcNTPDase1) plays essential roles in adhesion and infection and is a virulence factor. Quercetin is a flavonoid with antimicrobial, antiviral, and antitumor activities. Its potential as a partial inhibitor of NTPDases has also been demonstrated. In this work, we synthesized the non-natural L-glycoside derivatives of quercetin and evaluated them as inhibitors of recombinant TcNTPDase1 (rTcNTPDase1). These compounds, and quercetin and miquelianin, a natural quercetin derivative, were also tested. Compound 16 showed the most significant inhibitory effect (94%). Quercetin, miquelianin, and compound 14 showed inhibition close to 50%. We thoroughly investigated the inhibitory effect of 16. Our data suggested a competitive inhibition with a Ki of 8.39 μM (± 0.90). To better understand the interaction of compound 16 and rTcNTPDase1, we performed molecular dynamics simulations of the enzyme and docking analyses with the compounds. Our predictions show that compound 16 binds to the enzyme's catalytic site and interacts with important residues for NTPDase activity. As an inhibitor of a critical T. cruzi enzyme, (16) could be helpful as a starting point in the developing of a future treatment for Chagas disease. Furthermore, the discovery of (16) as an inhibitor of TcNTPDase1 may open new avenues in the study and development of new inhibitors of E-NTPDases.

Indexed as

FlavonoidsTrypanosoma cruziChagas DiseaseEnzyme InhibitorsGlycosidesMolecular Docking SimulationEnzyme InhibitorsFlavonoidsGlycosidesChagas DiseaseE-NTPDaseent-quercetin derivativesInhibitorsmolecular dockingTcNTPDase-1

Identifiers

PMID37975950
PMCPMC11303637
OpenAlexW4388772169

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.